Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease.
Eric McDade, Guoqiao Wang, Brian A Gordon...
https://pubmed.ncbi.nlm.nih.gov/30217935/Actively Recruiting
Led by Washington University School of Medicine · Updated on 2026-07-27
280
Participants Needed
37
Research Sites
21 weeks
Total Duration
Researchers are evaluating investigational study drugs for people with a genetic mutation that causes Alzheimers disease AD. The study focuses on those who either carry this mutation or are at risk but unaware of their genetic status. It aims to assess whether these drugs can prevent or slow the buildup of amyloid beta Ab2 plaques in the brain and later evaluate the impact on other Alzheimers disease biomarkers and disease progression. Participants will receive subcutaneous injections of remternetug or a matching placebo every 12 weeks during Stage 1, which is a blinded, placebo-controlled period lasting up to 4 years. After this, Stage 2 is an open-label period of 4 years where all mutation carriers will receive the active drug. Those initially on placebo will follow the same dose escalation as Stage 1, while those on active drug will continue their established dose. The design includes randomization and blinding for treatment and mutation status, with a shared placebo group across study arms. During the study, participants will undergo regular clinical and cognitive assessments, magnetic resonance imaging MRI, amyloid PET imaging, and cerebrospinal fluid CSF analysis. Researchers will monitor amyloid beta accumulation, downstream biomarkers like tau proteins and neurofilament light, and subtle cognitive changes. Safety, tolerability, and adherence will also be tracked. The total participation can last up to 8 years, including both treatment stages and follow-up assessments.
CONDITIONS
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
J
Jamie Bartzel
E
Ellen Ziegemeier
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Washington University School of Medicine
Lead Sponsor
Alzheimer's Association
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Remternetug (SC), every 12 weeks | Matching Placebo (Remternetug), every 12 weeks |
|---|---|---|
| What it is | An anti-amyloid immunotherapy, remternetug is delivered by subcutaneous injection every 12 weeks. It targets amyloid-beta build-up associated with autosomal-dominant Alzheimer's disease. | A placebo comparator designed to match remternetug injections in appearance and schedule, but contains no active anti-amyloid agent. |
| Role in the trial | Serves as the investigational treatment arm, aiming to prevent or slow amyloid-beta accumulation in people at high genetic risk. | Functions as the control arm to enable comparison of remternetug's effects on amyloid-beta and downstream biomarkers. |
| Primary use | Investigated as a potential disease-modifying therapy to delay or prevent early biomarker changes leading to Alzheimer's disease. | Used as a comparator to assess remternetug's impact on biomarker changes and cognitive outcomes. |
| How it is given or performed | Remternetug is administered as a subcutaneous injection every 12 weeks. | The placebo is delivered by subcutaneous injection every 12 weeks, matching remternetug in procedure. |
| Evidence status | Current efficacy and clinical outcome data for remternetug in presymptomatic autosomal-dominant Alzheimer's disease are not yet established. Previous anti-amyloid antibody trials in AD have shown biomarker effects, but clinical benefit remains to be validated in this context. | Placebo controls enable rigorous assessment of therapeutic impact, but do not affect disease biomarkers or progression. |
| Important limitations | Potential effectiveness in presymptomatic, autosomal-dominant Alzheimer's disease is uncertain. Disease-modifying treatment results in this population are not yet established. The trial targets people with normal cognition, so outcomes may differ from symptomatic AD populations. Biomarker change does not always translate to cognitive benefit. | Placebo does not slow or prevent biomarker or cognitive changes. The lack of active treatment in this arm means participants do not receive potential disease-modifying therapy, but serve an essential comparison role. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 4 years
Participants receive either remternetug or matching placebo by subcutaneous injection every 12 weeks during a blinded period lasting up to 4 years.
Visits every 12 weeks for injections and assessments
Duration - 4 years
All mutation carriers receive remternetug in an open-label phase lasting 4 years. Those initially on placebo follow the same dose escalation schedule as Stage 1, while those on active drug continue their established dose.
Regular injections and safety assessments every 12 weeks
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Eric McDade, Guoqiao Wang, Brian A Gordon...
https://pubmed.ncbi.nlm.nih.gov/30217935/Alexandra L Young, Neil P Oxtoby, Pankaj Daga...
https://pubmed.ncbi.nlm.nih.gov/25012224/Guoqiao Wang, Scott Berry, Chengjie Xiong...
https://pubmed.ncbi.nlm.nih.gov/29761523/Davis C Ryman, Natalia Acosta-Baena, Paul S Aisen...
https://pubmed.ncbi.nlm.nih.gov/24928124/Hua Weng, Randall Bateman, John C Morris...
https://pubmed.ncbi.nlm.nih.gov/29250611/Joshua D Grill, Randall J Bateman, Virginia Buckles...
https://pubmed.ncbi.nlm.nih.gov/26203303/Ronald B Demattos, Jirong Lu, Ying Tang...
https://pubmed.ncbi.nlm.nih.gov/23217740/Randall J Bateman, Chengjie Xiong, Tammie L S Benzinger...
https://pubmed.ncbi.nlm.nih.gov/22784036/S M Mills, J Mallmann, A M Santacruz...
https://pubmed.ncbi.nlm.nih.gov/24016464/Stacie Weninger, Maria C Carrillo, Billy Dunn...
https://pubmed.ncbi.nlm.nih.gov/27157073/Washington University School of Medicine
Lead Sponsor
Alzheimer's Association
Collaborating Sponsor